Heparin-induced thrombocytopenia: a rare presentation with skin necrosis
https://doi.org/10.4081/dr.2023.9855
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Heparin-induced thrombocytopenia is the most clinically relevant non-haemorrhagic complication of heparin and is characterised by the presence of anti-PF4/heparin-IgG antibodies. The circulating PF4/heparin-IgG immune complex binds to platelets via their FcyIIa receptors, activating them and promoting their aggregation, with consequent platelet consumption, thrombocytopenia and thrombotic phenomena. Despite thrombocytopenia, this condition is not typically associated with bleeding complications. Instead, thrombosis is the most serious complication of Heparin-induced thrombocytopenia, contributing to increased morbidity and mortality. Thrombotic events can be venous and arterial, such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and thrombotic stroke. Skin necrosis at the site of heparin injections is a rare but well-described manifestation of Heparin-induced thrombocytopenia. We report a case of Heparin-induced thrombocytopenia presented as skin necrosis, highlighting the importance of recognising this potentially fatal condition and the need for an immediate cessation of all sources of heparin and its replacement by other anticoagulants.
Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007;83(983):575–82. DOI: https://doi.org/10.1136/pgmj.2007.059188
Hogan M, Berger J. Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management. Vascular Medicine. 2020;25(2):160-73. DOI: https://doi.org/10.1177/1358863X19898253
Arepally G. Heparin-induced thrombocytopenia. Blood. 2017;129(21):2864-72. DOI: https://doi.org/10.1182/blood-2016-11-709873
Handschin A, Trentz O, Kock H, et al. Low molecular weight heparin-induced skin necrosis- a systemic review. Langenbecks Arch Surg. 2005;390:249-54. DOI: https://doi.org/10.1007/s00423-004-0522-7
Tietge U, Schmidt H, Jäckel C, et al. LMWH-induced skin necrosis occurring distant from injection sites and without thrombopenia. J Intern Med. 1998;243:313–15. DOI: https://doi.org/10.1046/j.1365-2796.1998.00304.x
White P, Sadd J, Nensel R. Thrombotic complications of heparin therapy: including six cases of heparin--induced skin necrosis. Ann Surg. 1979;190(5):595-608. DOI: https://doi.org/10.1097/00000658-197911000-00007
Warkentin T. Heparin-induced skin lesions. Br J Haematol. 1996;92(2):494-97. DOI: https://doi.org/10.1046/j.1365-2141.1996.d01-1481.x
Warkentin T, Roberts R, Hirsh J, et al. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005;127(5):1857-61. DOI: https://doi.org/10.1378/chest.127.5.1857
Katsourakis A, Noussios G, Kapoutsis G, et al. Low molecular weight heparin-induced skin necrosis: a case report. Case Rep Med. 2011;2011:857391. DOI: https://doi.org/10.1155/2011/857391
Bertrand P, Perbet S, Sapin A, et al. Heparin-induced skin necrosis: HIT-2 without thrombocytopenia. Intensive Care Med. 2011;37:172–73. DOI: https://doi.org/10.1007/s00134-010-2027-x
Warkentin T, Pai M, Linkins L. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104-113. DOI: https://doi.org/10.1182/blood-2017-04-778993
Cuker A, Arepally G, Chong B, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Advances. 2018;2(22):3360-92. DOI: https://doi.org/10.1182/bloodadvances.2018024489
Supporting Agencies
no financial supportCopyright (c) 2023 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
